Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Cepheid (CPHD - Analyst Report) disclosed preliminary results for the second quarter of 2013 based on current projections. The molecular diagnostic company is slated to release exhaustive second-quarter results on Jul 18.

A Look at Elementary Results for 2Q13

For the second quarter, Cepheid estimates adjusted earnings per share of 2 cents compared with adjusted earnings of 11 cents in the year-ago quarter. However, this excludes stock-based compensation of about $6.5 million in the quarter. Including the stock-based compensation, the current Zacks Consensus Estimate is pegged at loss of 2 cents per share.

On a reported basis, the company estimates net loss of $6.6 million or 10 cents per share in the quarter under review, worse than the net income of $1.1 million or 2 cents per share in the prior-year quarter.

The company expects revenues of about $96 million, a record high for Cepheid. This is substantially higher than the year-ago revenues of $81 million and the current Zacks Consensus Estimate of $92 million. Growth was led by higher-than-expected revenues from High Burden Developing Countries (HBDC) and robust growth in overseas commercial clinical business.  

Among the segments, Cepheid envisages commercial clinical revenues to be around $70 million and revenues from non-clinical franchise to be $9 million. Revenues from HBDC are estimated at $17 million for the second quarter, another new peak for the company.  

Commercial clinical revenues were primarily driven by higher sales of reagents (up 17% year over year to $60 million) on the back of stronger Xpert growth (up 22% year over year). As per management, North American commercial clinical revenues came in at the lower end of Cepheid’s expectations.

On a sequential basis, commercial clinical reagents revenues were flat. Growth (up $4 million) was negated by an expected decline in Xpert Flu sales (down $3 million) due to seasonality of flu and lower revenues from non-Xpert test. Moreover, placements of 53 commercial systems in North America and 156 systems in the overseas market are expected in the quarter under review accounting for $10 million of commercial clinical system revenues. System placements were aided by three consecutive quarters of backorders due to supply lag on account of manufacturing disruption for most of the second half of 2012.

Our View

The sales growth reflects a favorable amalgamation of Cepheid’s effort to return to normal manufacturing operations and solid demand in end-markets. The ongoing efforts on capacity expansion should enable the company to meet the currently assessed soaring market demand for its offerings.

Although HBDC revenues improved in the quarter, we are wary about the impact of this low-margin business on the gross margin. Moreover, Cepheid posted loss after two successive quarters of profitable growth.

The company expects to launch a gamut of tests in the U.S. as well as the overseas market in 2013. In our opinion, test menu expansion is a significant growth catalyst for this molecular diagnostic company. We believe that Cepheid’s valuation will be boosted by its healthy pipeline and periodic product launches going forward.

The stock carries a Zacks Rank #2 (Buy). Other Zacks Rank #2 stocks such as Edwards Lifesciences Corp. (EW - Analyst Report) and MAKO Surgical Corp. are likely to do well. ResMed Inc. (RMD - Analyst Report), carrying a Zacks Rank #1 (Strong Buy) also warrants a look.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%